Insulin-like Growth Factor-I Receptor Blockade Reduces the Invasiveness of Gastrointestinal Cancers Via Blocking Production of Matrilysin
Overview
Authors
Affiliations
Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. We have previously shown significant therapeutic activity for recombinant adenoviruses expressing dominant-negative insulin-like growth factor-I receptor (IGF-IR/dn), including suppression of tumor invasion. In this study, we sought to evaluate the mechanism of inhibition of invasion and the relationship between IGF-IR and matrix metalloproteinase (MMP) activity in GI carcinomas. We analyzed the role of IGF-IR on invasion in three GI cancer cell lines, colorectal adenocarcinoma, HT29; pancreatic adenocarcinoma, BxPC3 and gastric adenocarcinoma, MKN45, using a modified Boyden chamber method and subcutaneous xenografts in nude mice. The impact of IGF-IR signaling on the expression of MMPs and the effects of blockade of matrilysin or IGF-IR on invasiveness were assessed using recombinant adenoviruses, a tyrosine kinase inhibitor NVP-AEW541 and antisense matrilysin. Invasive subcutaneous tumors expressed several MMPs. IGF-IR/dn reduced the expression of these MMPs but especially matrilysin (MMP-7). Insulin-like growth factor (IGF) stimulated secretion of matrilysin and IGF-IR/dn blocked IGF-mediated matrilysin induction in three GI cancers. Both IGF-IR/dn and inhibition of matrilysin reduced in vitro invasion to the same degree. NVP-AEW541 also reduced cancer cell invasion both in vitro and in murine xenograft tumors via suppression of matrilysin. Thus, blockade of IGF-IR is involved in the suppression of cancer cell invasion through downregulation of matrilysin. Strategies of targeting IGF-IR may have significant therapeutic utility to prevent invasion and progression of human GI carcinomas.
Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.
Oliveres H, Pesantez D, Maurel J Int J Mol Sci. 2021; 22(9).
PMID: 34065119 PMC: 8126031. DOI: 10.3390/ijms22095019.
Bulutay P, Akyurek N, Memis L Turk Patoloji Derg. 2020; 37(1):7-17.
PMID: 32876329 PMC: 10508933. DOI: 10.5146/tjpath.2020.01503.
Garalla H, Lertkowit N, Tiszlavicz L, Reisz Z, Holmberg C, Beynon R Physiol Rep. 2018; 6(10):e13683.
PMID: 29845775 PMC: 5974721. DOI: 10.14814/phy2.13683.
Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J Neoplasia. 2018; 20(7):678-686.
PMID: 29842993 PMC: 6030389. DOI: 10.1016/j.neo.2018.05.004.
Type I insulin-like growth factor receptor signaling in hematological malignancies.
Vishwamitra D, George S, Shi P, Kaseb A, Amin H Oncotarget. 2016; 8(1):1814-1844.
PMID: 27661006 PMC: 5352101. DOI: 10.18632/oncotarget.12123.